CEACAM5 and neoplasm: In addition to the high-risk factors outlined by the NCCN guidelines, we assessed the relevance of common clinical indicators, including the total proportion of solid and micropapillary components (TPSM) of the tumor, the presence of driver mutations, tumor mutational burden (TMB), PD-L1 expression, and carcinoembryonic antigen (CEA) levels.